Shares of pSivida Corp. (NASDAQ:PSDV) have earned a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $7.67.

A number of brokerages recently weighed in on PSDV. B. Riley set a $5.00 target price on shares of pSivida and gave the stock a “buy” rating in a research note on Friday, December 15th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of pSivida in a research note on Wednesday, September 27th. ValuEngine downgraded shares of pSivida from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Laidlaw started coverage on shares of pSivida in a research note on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Northland Securities reaffirmed a “buy” rating and issued a $10.00 price target on shares of pSivida in a research note on Monday, December 11th.

A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP purchased a new stake in pSivida Corp. (NASDAQ:PSDV) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned approximately 0.18% of pSivida at the end of the most recent quarter. 9.70% of the stock is owned by hedge funds and other institutional investors.

pSivida (NASDAQ PSDV) opened at $1.07 on Thursday. pSivida has a 52 week low of $1.02 and a 52 week high of $2.45. The firm has a market cap of $48.42, a price-to-earnings ratio of -2.33 and a beta of 1.34.

pSivida (NASDAQ:PSDV) last announced its earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). pSivida had a negative net margin of 226.31% and a negative return on equity of 139.56%. The business had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.74 million. equities analysts anticipate that pSivida will post -0.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “pSivida Corp. (PSDV) Given Average Rating of “Buy” by Analysts” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at

About pSivida

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Analyst Recommendations for pSivida (NASDAQ:PSDV)

Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with Analyst Ratings Network's FREE daily email newsletter.